US › Healthcare

Foghorn Therapeutics Inc (FHTX)

US · Healthcare · Biotechnology

$4.20+0.72%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$16.1M

Revenue YoY

+112.7%

Net profit

$-7.2M

EPS

$-0.10

EPS estimate

$-0.23

Net margin

-44.7%

EPS came in at -0.10 against a street estimate of -0.23 — a beat of 56.5%.

Key statistics

Market cap

$244.7M

Forward P/E

0.0

P/B

2,005.35

Book value

$-1.38

EPS (TTM)

$-0.94

52-week high

$7.61

52-week low

$3.27

50-day MA

$5.60

200-day MA

$5.10

Beta

2.86

Analyst view

Analysts rate Foghorn Therapeutics Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $11.44.

Shareholding

Insiders

14.13%

Institutions

76.67%

Largest institutional holders

Fund	Stake
Flagship Ventures Management, Inc.	21.34%
FMR Inc	10.18%
Bvf Inc	9.84%
Deerfield Management Co	7.40%
BlackRock Inc	3.98%
Euclidean Capital LLC	2.65%
Vanguard Capital Management, LLC	2.52%
Geode Capital Management, LLC	1.43%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Foghorn Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.